VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Updates in immunotherapy for multiple myeloma: BiTEs & novel targets

Adam Sperling, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, shares his thoughts on the most exciting developments in the field of immunotherapy for multiple myeloma, including BCMA-targeting CAR-T therapies, bispecific T-cell engagers (BiTEs), and novel target antigens. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter